Hutchmed China Ltd - Company Profile
Powered by 
All the data and insights you need on Hutchmed China Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Hutchmed China Ltd Strategy Report
- Understand Hutchmed China Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Hutchmed China Ltd (Hutchmed) formerly known as Hutchison China MediTech Ltd is a biopharmaceutical company that discovers, develops, manufactures, and commercializes drugs for the treatment of solid tumors and hematological malignancies, and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe, and Australia. The company offers prescription drugs to hospitals in China through a direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.
Headquarters
Hong Kong
Address
48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong
Website
www.hutch-med.com
Telephone
852 212 81188
No of Employees
1,988
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
13 (HKG)
Revenue (2022)
$838.0M
96.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
127.9%
(2022 vs 2021)
Market Cap*
$3.0B
Net Profit Margin (2022)
XYZ
114.2%
(2022 vs 2021)
* As of and is in US$
Hutchmed China Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Marketed | Baiyunshan |
| Fruquitnib | Shang Yao |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In January, the company secured approval from the Pharmacy and Poisons Board of Hong Kong for ELUNATE for the treatment of adult patients with previously treated metastatic colorectal cancer. |
| 2023 | Contracts/Agreements | In April, the company signed an agreement to initiate the registration phase of the ongoing Phase II trial of HMPL-453 for intrahepatic cholangiocarcinoma patients with fibroblast growth factor receptors 2 fusion. |
| 2023 | Contracts/Agreements | In January, HUTCHMED Limited entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau. |
Competitor Comparison
| Key Parameters | Hutchmed China Ltd | Sinopharm Group Co Ltd | Shanghai Pharmaceuticals Holding Co Ltd | Yunnan Baiyao Group Co Ltd | Shijiazhuang Yiling Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | China | China | China | China |
| City | Hong Kong | Shanghai | Shanghai | Kunming | Shijiazhuang |
| State/Province | - | Shanghai | Shanghai | Yunnan | Hebei |
| No. of Employees | 1,988 | 115,959 | 48,164 | 8,834 | 15,074 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Simon Chi Keung To | Director; Chairman | Executive Board | 2006 | 71 |
| Weiguo Su, Ph.D. | Director; Chief Scientific Officer; Chief Executive Officer | Executive Board | 2022 | 65 |
| Johnny Chig Fung Cheng | Chief Financial Officer; Director | Executive Board | 2011 | 56 |
| Karen Jane Atkin | Executive Vice President; Chief Operating Officer | Senior Management | 2021 | 57 |
| Hong Chen | Chief Commercial Officer - China; Senior Vice President | Senior Management | 2018 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward